Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Virax Biolabs Group Ltd VRAX

Healthcare
Virax Biolabs Group Limited is a biotechnology company. The Company is primarily engaged in the sales, distribution and marketing of diagnostics test kits and medical technology for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. It is developing a T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral threats. Its product portfolio includes: ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.


NDAQ:VRAX - Post by User

Virax Biolabs Group Ltd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(57)
•••
Post by Iseneschalon Apr 19, 2023 10:41am
42 Views
Post# 35402906

VRAX.....Monkey Pox play ?????

VRAX.....Monkey Pox play ?????The IPO was done at $5.........I'd say all the Investors look like a "Bunch of Monkeys"

They all want their money back......what a joke !!!!!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities